Biomarkers only become useful when the assay behind them is reproducible and the analysis behind the result is honest about uncertainty. We treat both halves as one problem.
By validating panels against traceable controls and modelling the data with the right statistical approach, we help clinical teams move from a noisy signal to an endpoint they can act on.
The payoff is earlier, better-supported decisions — and a data trail that holds up under review.